Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

EXEL

Exelixis Inc

Nov 29 • 10:35AM ET

21.35

Dollar change +0.30
Percentage change 1.43	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	76.09	EPS (ttm)	0.28	Insider Own	2.97%	Shs Outstand	323.95M	Perf Week	0.61%
Market Cap	6.64B	Forward P/E	21.40	EPS next Y	1.00	Insider Trans	-2.23%	Shs Float	301.75M	Perf Month	5.48%
Income	92.07M	PEG	4.00	EPS next Q	0.21	Inst Own	85.61%	Short Float / Ratio	3.21% / 4.27	Perf Quarter	-5.11%
Sales	1.77B	P/S	3.74	EPS this Y	11.99%	Inst Trans	-1.93%	Short Interest	9.70M	Perf Half Y	10.74%
Book/sh	7.55	P/B	2.83	EPS next Y	59.07%	ROA	3.10%	Target Price	25.82	Perf Year	27.16%
Cash/sh	3.55	P/C	6.02	EPS next 5Y	19.00%	ROE	3.81%	52W Range	15.32 - 22.80	Perf YTD	33.10%
Dividend	-	P/FCF	18.07	EPS past 5Y	2.77%	ROI	3.63%	52W High	-6.34%	Beta	0.55
Dividend %	-	Quick Ratio	3.76	Sales past 5Y	32.32%	Gross Margin	96.24%	52W Low	39.36%	ATR	0.54
Employees	1223	Current Ratio	3.83	Sales Q/Q	14.62%	Oper. Margin	2.31%	RSI (14)	52.55	Volatility	1.89% 2.46%
Optionable	Yes	Debt/Eq	0.08	EPS Q/Q	-98.53%	Profit Margin	5.19%	Rel Volume	0.53	Prev Close	21.05
Shortable	Yes	LT Debt/Eq	0.08	Earnings	Nov 01 AMC	Payout	0.00%	Avg Volume	2.27M	Price	21.35
Recom	1.61	SMA20	1.40%	SMA50	0.58%	SMA200	7.31%	Volume	250,710	Change	1.43%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-26-23	Initiated	H.C. Wainwright	Buy	$28
Aug-22-23	Reiterated	Oppenheimer	Outperform	$25 → $29
Aug-08-23	Initiated	SVB Securities	Market Perform	$18
Jul-11-23	Resumed	Morgan Stanley	Equal-Weight	$21
May-10-23	Resumed	Piper Sandler	Overweight	$28
Mar-09-23	Initiated	Wells Fargo	Overweight	$23
Jan-26-23	Initiated	Credit Suisse	Outperform	$29
Oct-18-22	Initiated	JMP Securities	Mkt Outperform	$26
Jun-24-22	Initiated	BMO Capital Markets	Outperform	$28
Nov-19-21	Initiated	Piper Sandler	Overweight	$34
Nov-03-21	Resumed	Jefferies	Buy	$28
Oct-07-21	Initiated	Jefferies	Buy	$28
Aug-06-21	Reiterated	H.C. Wainwright	Buy	$35 → $64
Jun-15-21	Initiated	H.C. Wainwright	Buy	$47
May-18-21	Resumed	Goldman	Sell	$23
Mar-31-21	Initiated	Credit Suisse	Outperform	$30
Mar-12-21	Initiated	Wolfe Research	Outperform	$35
Mar-04-20	Initiated	Barclays	Overweight	$26
Jan-13-20	Initiated	SunTrust	Buy	$31
Nov-13-19	Initiated	BofA/Merrill	Buy	$22

Show Previous Ratings

Today 10:45AM	Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment (PR Newswire)
Nov-21-23 04:05PM	Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023 (Business Wire)
Nov-17-23 01:33PM	Exelixis (EXEL) Gains 30% YTD on Cabometyx, Pipeline Progress (Zacks)
Nov-10-23 09:00AM	Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023 (Business Wire)
Nov-09-23 04:43PM	Under the Microscope: 3 Biotech Stocks Pioneering Tomorrows Cures (InvestorPlace)
05:24PM	Loading…
Nov-08-23 05:24PM	3 Biotech Stocks With the Strongest Clinical Pipelines (InvestorPlace)
05:19AM	3 Promising Biotech Stocks Flying Under the Radar (InvestorPlace)
Nov-06-23 09:47AM	Exelixis, Inc. (NASDAQ:EXEL) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 12:11PM	Analyst Report: Exelixis, Inc. (Morningstar Research)
Nov-02-23 11:23AM	Exelixis (EXEL) Q3 Earnings and Sales Miss, Annual View Updated (Zacks)
12:30AM	Exelixis (EXEL) Q3 2023 Earnings Call Transcript (Motley Fool)
Nov-01-23 07:00PM	Compared to Estimates, Exelixis (EXEL) Q3 Earnings: A Look at Key Metrics (Zacks)
06:05PM	Exelixis Inc (EXEL) Reports Q3 2023 Earnings: Total Revenues of $471.9 Million (GuruFocus.com)
04:05PM	Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update (Business Wire)
Oct-30-23 10:00AM	My Sights Are Locked on 3 Biotech Plays as the End of the Year Nears (TheStreet.com)
05:06AM	Loading…
Oct-28-23 05:06AM	4 Dominant Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Oct-27-23 04:58AM	Strength Seen in Exelixis (EXEL): Can Its 5.6% Jump Turn into More Strength? (Zacks)
Oct-26-23 10:02AM	Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for (Zacks) +5.58%
Oct-25-23 10:01AM	Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for (Zacks)
08:30AM	Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030 (PR Newswire)
Oct-22-23 02:30AM	Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023 (Business Wire)
Oct-19-23 06:51PM	Analyst Report: Exelixis, Inc. (Morningstar Research)
08:15AM	3 Under-the-Radar Biotech Stocks to Buy in 2023 (Motley Fool)
Oct-18-23 04:05PM	Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023 (Business Wire)
08:30AM	Is Exelixis Stock a Buy Now? (Motley Fool)
Oct-12-23 11:40AM	EXEL vs. TECH: Which Stock Is the Better Value Option? (Zacks)
Oct-09-23 02:03AM	14 Best Cancer Stocks To Buy Now (Insider Monkey)
Oct-02-23 09:49AM	Steady Eddies: 3 Low Beta Stocks for Long-Haul Gains (InvestorPlace)
Sep-20-23 02:15PM	3 Biotech Stocks That Should Be on Every Investors Radar This Fall (InvestorPlace)
Sep-18-23 09:16AM	GSK's Momelotinib Gets FDA Nod for Myelofibrosis-Related Anemia (Zacks)
05:06AM	Loading…
Sep-16-23 05:06AM	4 Magnificent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Sep-15-23 10:23AM	2 Top Biotech Stocks Defying the Bear Market (Motley Fool)
Sep-13-23 11:23AM	Exelixis (EXEL) Gets Rights for Tumor Candidate From Insilico (Zacks)
08:29AM	Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor (PR Newswire)
Sep-12-23 08:00AM	Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor (Business Wire)
Sep-11-23 12:31PM	J&J (JNJ) Seeks Approval for Bladder Cancer Drug in Europe (Zacks)
Sep-08-23 11:30AM	Illumina (ILMN) Down 14.2% Since Last Earnings Report: Can It Rebound? (Zacks)
Sep-07-23 08:43AM	J&J (JNJ) to End Pulmonary Hypertension Study on Opsumit (Zacks)
Sep-06-23 09:33AM	AstraZeneca (AZN) Gets FDA CRL for Ultomiris in New Indication (Zacks)
Sep-05-23 11:40AM	EXEL vs. ILMN: Which Stock Is the Better Value Option? (Zacks)
09:40AM	Biogen's (BIIB) Stock Outperforms Industry YTD: Here's Why (Zacks)
Sep-04-23 10:34AM	Exelixis (EXEL) Stock Gains 41.8% So Far in 2023: Here's Why (Zacks)
Sep-01-23 11:31AM	Why Is Blueprint Medicines (BPMC) Down 2% Since Last Earnings Report? (Zacks)
09:18AM	5 Biotech Stocks to Buy as New Drug Approvals Drive Industry Prospects (Zacks)
Aug-31-23 04:05PM	Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September (Business Wire)
11:31AM	Why Is Exelixis (EXEL) Up 10.6% Since Last Earnings Report? (Zacks)
Aug-30-23 08:00AM	The Top Healthcare Stocks to Buy With $100 (Motley Fool)
Aug-29-23 06:52PM	Analyst Report: Exelixis, Inc. (Morningstar Research)
08:02AM	Top 5 High-Flying Mid-Cap Stocks Despite a Volatile August (Zacks)
Aug-28-23 09:30AM	Too Many Investors Have Become Too Complacent About 'Higher for Longer' (TheStreet.com)
Aug-25-23 11:49AM	Exelixis (EXEL) Late-Stage Study in Pancreatic Tumors Positive (Zacks)
Aug-24-23 08:00AM	Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors (Business Wire)
07:30AM	2 No-Brainer Biotech Stocks to Buy Right Now (Motley Fool)
Aug-23-23 04:30PM	Exelixis Announces Appointment of Amy Peterson, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer (Business Wire)
Aug-21-23 04:20PM	These Are the ONLY 3 Biotech Stocks to Consider in August 2023 (InvestorPlace)
11:10AM	Exelixis' (EXEL) Prostate Cancer Study Meets Primary Endpoint (Zacks)
01:00AM	Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer (Business Wire)
Aug-18-23 11:40AM	EXEL or ILMN: Which Is the Better Value Stock Right Now? (Zacks)
Aug-15-23 01:43PM	Here's Why Exelixis (EXEL) is a Strong Value Stock (Zacks)
Aug-14-23 03:25PM	Exelixis Stock Sees Rising Relative Strength Rating (Investor's Business Daily)
Aug-12-23 10:04AM	Exelixis (NASDAQ:EXEL) investors are up 6.2% in the past week, but earnings have declined over the last five years (Simply Wall St.)
Aug-11-23 07:15PM	Analyst Report: Exelixis, Inc. (Morningstar Research)
12:20PM	Surging Earnings Estimates Signal Upside for Exelixis (EXEL) Stock (Zacks)
Aug-10-23 09:15AM	ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue? (Zacks)
Aug-08-23 11:37PM	3 Biotech Stocks Youll Regret Not Buying Soon (InvestorPlace)
10:49AM	Exelixis Stock Flashes Improved Relative Price Strength With Upgrade (Investor's Business Daily)
10:02AM	DraftKings upgraded, Home Depot downgraded: Wall Street's top analyst calls (The Fly)
Aug-06-23 07:00AM	Getting Another Shot of Biotech Dynavax Technologies (TheStreet.com)
Aug-02-23 12:20PM	Exelixis, Inc. (NASDAQ:EXEL) Q2 2023 Earnings Call Transcript (Insider Monkey)
12:17PM	Exelixis (EXEL) Q2 Earnings Top, Cabometyx Drives Growth (Zacks)
12:00AM	Exelixis (EXEL) Q2 2023 Earnings Call Transcript (Motley Fool)
Aug-01-23 07:30PM	Exelixis (EXEL) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
05:55PM	Exelixis (EXEL) Tops Q2 Earnings and Revenue Estimates (Zacks)
04:51PM	Exelixis: Q2 Earnings Snapshot (AP Finance)
04:05PM	Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update (Business Wire)
Jul-31-23 09:58AM	Drug, Biotech Stocks' Q2 Earnings Due on Aug 1: PFE, MRK & More (Zacks)
Jul-27-23 07:30AM	2 Biotech Growth Stocks I'd Buy Right Now (Motley Fool)
Jul-26-23 11:30AM	2 Biotech Stocks to Watch as Their Growth Stories Brighten (TheStreet.com)
Jul-25-23 11:40AM	EXEL or RGEN: Which Is the Better Value Stock Right Now? (Zacks)
10:01AM	Exelixis (EXEL) Reports Next Week: What You Should Expect (Zacks)
Jul-24-23 03:06PM	Exelixis deal sets generic version of cancer drug for release in 2031 (American City Business Journals)
Jul-23-23 04:00PM	Exelixis, Inc. Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (Business Wire)
11:44AM	11 Best Healthcare Stocks Under $50 (Insider Monkey)
Jul-20-23 08:08AM	The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023 (InvestorPlace)
Jul-18-23 04:05PM	Exelixis to Release Second Quarter 2023 Financial Results on Tuesday, August 1, 2023 (Business Wire)
Jun-21-23 08:00PM	EXEL: What does Argus have to say about EXEL? (Argus Research)
05:21AM	3 No-Brainer Stocks to Buy With $200 Right Now (Motley Fool)
Jun-08-23 11:30AM	Why Is Exelixis (EXEL) Down 0.6% Since Last Earnings Report? (Zacks)
May-31-23 12:30PM	Farallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis Board (Business Wire)
May-30-23 04:05PM	Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June (Business Wire)
May-29-23 11:58AM	Exelixis, Inc.'s (NASDAQ:EXEL) market cap decline of US$208m may not have as much of an impact on institutional owners after a year of 4.0% returns (Simply Wall St.)
09:00AM	The Smartest Stocks to Buy With $20 Right Now and Hold Forever (Motley Fool)
May-24-23 09:53AM	2 Under-the-Radar Biotech Stocks to Buy in 2023 (Motley Fool)
May-20-23 09:30AM	2 Unstoppable Growth Stocks to Buy in 2023 and Beyond (Motley Fool)
May-13-23 05:06AM	Nasdaq Bear Market: 5 Exceptional Growth Stocks You'll Regret Not Buying on the Dip (Motley Fool)
May-12-23 07:55AM	Exelixis, Inc. (NASDAQ:EXEL) Shares Could Be 49% Below Their Intrinsic Value Estimate (Simply Wall St.)
May-10-23 02:52PM	Exelixis (EXEL) Q1 Earnings Miss, Revenues Increase Y/Y (Zacks)
02:00AM	Exelixis (EXEL) Q1 2023 Earnings Call Transcript (Motley Fool)
May-09-23 09:34PM	Analyst Report: Exelixis, Inc. (Morningstar Research)
08:30PM	Compared to Estimates, Exelixis (EXEL) Q1 Earnings: A Look at Key Metrics (Zacks)

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Aftab Dana	CSO/EVP Disc & Trans Research	Aug 30	Sale	22.47	4,600	103,362	399,943	Sep 01 08:15 PM
MORRISSEY MICHAEL	President and CEO	Aug 28	Option Exercise	15.31	360,000	5,511,600	945,496	Aug 30 09:48 PM
Senner Christopher J.	EVP and CFO	Aug 04	Option Exercise	14.74	60,000	884,400	631,631	Aug 07 09:20 PM
Senner Christopher J.	EVP and CFO	Aug 04	Sale	20.68	60,000	1,240,800	571,631	Aug 07 09:20 PM
Senner Christopher J.	EVP and CFO	Aug 03	Option Exercise	14.74	60,000	884,400	631,631	Aug 07 09:20 PM
Senner Christopher J.	EVP and CFO	Aug 03	Sale	20.51	60,000	1,230,600	571,631	Aug 07 09:20 PM
Haley Patrick J.	EVP, Commercial	Aug 03	Sale	20.67	30,553	631,531	285,467	Aug 07 08:24 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Aug 01	Option Exercise	14.74	55,710	821,165	627,686	Aug 03 08:02 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Aug 01	Sale	19.63	55,710	1,093,587	571,976	Aug 03 08:02 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Apr 05	Option Exercise	14.74	13,930	205,328	621,365	Apr 05 08:57 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Apr 05	Sale	20.01	38,930	778,989	582,435	Apr 05 08:57 PM
WYSZOMIERSKI JACK L	Director	Mar 10	Option Exercise	6.30	40,000	252,000	332,767	Mar 14 08:22 PM
WYSZOMIERSKI JACK L	Director	Mar 10	Sale	16.61	15,300	254,133	317,467	Mar 14 08:22 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Mar 01	Option Exercise	14.74	27,860	410,656	605,576	Mar 03 07:59 PM
Hessekiel Jeffrey	EVP, General Counsel & Sec	Mar 01	Sale	17.13	77,860	1,333,742	527,716	Mar 03 07:59 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Feb 28	Option Exercise	14.74	82,490	1,215,903	433,962	Mar 01 07:56 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Feb 28	Sale	17.50	82,490	1,443,575	351,472	Mar 01 07:56 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Feb 27	Option Exercise	14.74	10	147	351,482	Mar 01 07:56 PM
Aftab Dana	CSO/EVP Disc & Trans Research	Feb 27	Sale	17.50	10	175	351,472	Mar 01 07:56 PM
Garber Alan M	Director	Feb 21	Option Exercise	6.30	40,000	252,000	71,417	Feb 23 09:08 PM
Garber Alan M	Director	Feb 21	Sale	17.49	40,000	699,600	31,417	Feb 23 09:08 PM
FELDBAUM CARL B	Director	Feb 09	Option Exercise	6.30	40,000	252,000	58,701	Feb 10 07:56 PM
FELDBAUM CARL B	Director	Feb 09	Sale	17.78	40,000	711,200	18,701	Feb 10 07:56 PM
Haley Patrick J.	EVP, Commercial	Feb 06	Option Exercise	4.20	25,000	105,000	279,414	Feb 08 08:17 PM
Haley Patrick J.	EVP, Commercial	Feb 06	Sale	17.37	25,000	434,250	254,414	Feb 08 08:17 PM
MORRISSEY MICHAEL	President and CEO	Jan 24	Option Exercise	4.20	100,000	420,000	440,655	Jan 26 08:59 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Dec 15	Option Exercise	4.20	20,000	84,000	430,958	Dec 16 08:09 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Dec 15	Sale	15.88	20,000	317,600	410,958	Dec 16 08:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EXEL

Exelixis Inc

Upgrade your FINVIZ experience